
Sign up to save your podcasts
Or


In this episode, we explore the RADAR trial's findings on antipsychotic dose reduction in schizophrenia. Can patients with chronic schizophrenia safely reduce or discontinue their antipsychotic medications without increasing relapse risk? The trial's results challenge common assumptions about medication reduction and provide crucial guidance for clinical practice.
Faculty: Oliver Freudenreich, M.D. Host: Richard Seeber, M.D.
By Psychopharmacology Institute4.6
270270 ratings
In this episode, we explore the RADAR trial's findings on antipsychotic dose reduction in schizophrenia. Can patients with chronic schizophrenia safely reduce or discontinue their antipsychotic medications without increasing relapse risk? The trial's results challenge common assumptions about medication reduction and provide crucial guidance for clinical practice.
Faculty: Oliver Freudenreich, M.D. Host: Richard Seeber, M.D.

74 Listeners

142 Listeners

3,362 Listeners

160 Listeners

1,148 Listeners

1,351 Listeners

732 Listeners

168 Listeners

578 Listeners

472 Listeners

735 Listeners

12 Listeners

189 Listeners

150 Listeners

59 Listeners